- Home
- LOT vs IMNM Comparison
LOT vs IMNM Comparison
Compare LOT & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOT
- IMNM
- Stock Information
- Founded
- LOT 1948
- IMNM 2006
- Country
- LOT China
- IMNM United States
- Employees
- LOT N/A
- IMNM N/A
- Industry
- LOT
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- LOT
- IMNM Health Care
- Exchange
- LOT NYSE
- IMNM Nasdaq
- Market Cap
- LOT 956.3M
- IMNM 748.3M
- IPO Year
- LOT N/A
- IMNM 2020
- Fundamental
- Price
- LOT $2.14
- IMNM $8.76
- Analyst Decision
- LOT
- IMNM Strong Buy
- Analyst Count
- LOT 0
- IMNM 5
- Target Price
- LOT N/A
- IMNM $26.40
- AVG Volume (30 Days)
- LOT 173.5K
- IMNM 973.9K
- Earning Date
- LOT 06-10-2025
- IMNM 05-12-2025
- Dividend Yield
- LOT N/A
- IMNM N/A
- EPS Growth
- LOT N/A
- IMNM N/A
- EPS
- LOT N/A
- IMNM N/A
- Revenue
- LOT $924,349,000.00
- IMNM $10,938,000.00
- Revenue This Year
- LOT $40.53
- IMNM N/A
- Revenue Next Year
- LOT $87.99
- IMNM $542.22
- P/E Ratio
- LOT N/A
- IMNM N/A
- Revenue Growth
- LOT 36.13
- IMNM N/A
- 52 Week Low
- LOT $1.06
- IMNM $5.15
- 52 Week High
- LOT $13.50
- IMNM $16.81
- Technical
- Relative Strength Index (RSI)
- LOT 57.57
- IMNM 58.34
- Support Level
- LOT $1.99
- IMNM $7.83
- Resistance Level
- LOT $2.17
- IMNM $9.04
- Average True Range (ATR)
- LOT 0.17
- IMNM 0.53
- MACD
- LOT -0.02
- IMNM 0.07
- Stochastic Oscillator
- LOT 43.90
- IMNM 82.97
About LOT LOTUS TECHNOLOGY INC
Lotus Technology Inc is a battery electric vehicle (BEV) maker that designs, develops, and sells BEV lifestyle vehicles under the Lotus brand. The Group is also a distributor that sells luxury sports cars under the Lotus brand. It also provides other sales and ancillary services to customers.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.